Abstracts tagged "Arthritis"

Abstract Number: 462 • 2016 ACR/ARHP Annual Meeting
Selective Inhibition of MMP9 Using a Monoclonal Antibody As a Therapeutic Strategy for Rheumatoid Arthritis
Sunhwa Kim¹, Brian Carr¹, Leah Tong¹, Debi Jin¹, Ruth Wang¹, Derrek Marshall¹, David Gossage² and Victoria Smith¹, ¹Biology, Gilead Sciences, Inc., Foster city, CA, ²Biology, Gilead Sciences, Inc., foster city, CA
Background/Purpose: Matrix metalloproteinase-9 (MMP9), highly expressed by infiltrating inflammatory cells, pannus tissue, and multinucleated cells in the synovium and subchondral bone tissue, including osteoclasts, participates…
Abstract Number: 1455 • 2016 ACR/ARHP Annual Meeting
Collagen-Induced Arthritis and Uveitis in Mice Lacking TNF Receptors
Chiharu Iwahashi¹, Minoru Fujimoto², Tomoharu Ohkawara³, Hayato Urushima¹, Satoshi Serada¹ and Tetsuji Naka⁴, ¹Laboratory for Immune Signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan, ²Laboratry of immune signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan, ³Laboratory for immune signal, National Institute of Biomedical Innovation, Health and Nutrition, Osaka, Japan, ⁴Laboratory for immune signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan
Background/Purpose: Tumor necrosis factor (TNF) is a critical effector of the autoimmune inflammation in rheumatoid arthritis (RA) and uveitis. TNF inhibitors are preferably used in…
Abstract Number: 466 • 2016 ACR/ARHP Annual Meeting
Sexually Dimorphic Dysbiosis of Gut Microbiota in Tumor Necrosis Factor Transgenic Mice with Inflammatory-Erosive Arthritis
Richard Bell^1,2, Ronald Wood³, Christopher T. Ritchlin⁴, Edward Schwarz⁵ and Homaira Rahimi⁶, ¹Center for Musculoskelatal Research, University of Rochester, Rochester, NY, ²Pathology, University of Rochester, Rochester, NY, ³University of Rochester, Rochester, NY, ⁴Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵Orthopedeatrics, University of Rochester, Rochester, NY, ⁶Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Recent studies identify gut microbiota dysbiosis as a possible contributor to rheumatoid arthritis (RA) pathogenesis. RA patients have significantly different microbiomes than healthy controls.…
Abstract Number: 1477 • 2016 ACR/ARHP Annual Meeting
Exploring the Inadequate Cardiovascular Disease Prevention in Inflammatory Joint Diseases: Results from a Nationwide Norwegian Project
Eirik Ikdahl¹, Silvia Rollefstad², Grunde Wibetoe³, Anne Salberg⁴, Dag Magnar Soldal⁵, Inge C Olsen⁶, Tore K Kvien⁷, Anne Grete Semb¹ and Glenn Haugeberg⁸, ¹Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁵Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁶Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Martina Hansens Hospital, Bærum, Norway
Background/Purpose: Antihypertensives (antiHT) and lipid lowering therapies (LLT) prevent cardiovascular disease (CVD) effectively. It has been reported that patients with rheumatoid arthritis (RA) receive suboptimal…
Abstract Number: 3L • 2015 ACR/ARHP Annual Meeting
A Randomised Controlled Trial of the Clinical Effectiveness, Safety and Cost-Effectiveness of Adalimumab in Combination with Methotrexate for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis
Athimalaipet V Ramanan¹, Andrew D. Dick², Andrew McKay³, Ashley Jones⁴, Paula Williamson⁴, Sandrine Compeyrot-Lacassagne⁵, Ben Hardwick⁴, Helen Hickey⁴, Dyfrig Hughes⁶, Patricia Woo⁵, Diana Benton¹, Clive Edelsten⁵ and Michael W. Beresford⁷, ¹University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom, ²University of Bristol, Bristol Eye Hospital, Bristol, United Kingdom, ³Biostatistics, Clinical Trials Research Centre, University of Liverpool, Liverpool, United Kingdom, ⁴Clinical Trials Research Centre, University of Liverpool, Liverpool, United Kingdom, ⁵Great Ormond Street Hospital, London, United Kingdom, ⁶Bangor University, Bangor, United Kingdom, ⁷University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Uveitis associated with Juvenile Idiopathic Arthritis (JIA) is a major cause of morbidity with potentially sight-threatening complications. Despite current screening and (pre-biologic) therapeutic options,…
Abstract Number: 1244 • 2015 ACR/ARHP Annual Meeting
Extracellular MicroRNAs in Synovial Fluid Reveal a Marked Proliferative Signature in Patients with Antibiotic-Refractory Lyme Arthritis
Robert B. Lochhead, Nancy D. Kim, Sheila Arvikar, Klemen Strle and Allen C. Steere, Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Lyme arthritis (LA), caused by a tick-borne spirochete Borrelia burgdorferi, usually resolves appropriately with antibiotic treatment, called antibiotic-responsive LA. However, in some patients, arthritis…
Abstract Number: 2162 • 2015 ACR/ARHP Annual Meeting
Associations Between Education and Health Status Among Hispanics with Self-Reported Arthritis and/or Joint Pain
Leigha Vilen¹, Rebecca J. Cleveland², Alfredo Rivadeneira¹, Mary Altpeter³, Betsy Hackney⁴, Victoria Sepulveda² and Leigh F. Callahan⁴, ¹Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Institute on Aging, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC
Background/Purpose: Understanding the associations between education and health status among Hispanics with arthritis and/or joint pain is crucial in adapting existing arthritis interventions for this…
Abstract Number: 1345 • 2015 ACR/ARHP Annual Meeting
The Impact of Prior Antibiotic Treatment on Culture Results of Patients with Septic Arthritis
Ziv Paz¹, Sarah B. Lieber¹, Andrew Moore², Clara Zhu³, Mary Louise Fowler⁴ and Robert H. Shmerling⁵, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Medicine, Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, ³Medical School, Boston University School of Medicine, Boston, MA, ⁴School of Medicine, Boston University School of Medicine, Boston, MA, ⁵Medicine, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Synovial fluid culture and gram stain offer the most compelling proof of septic arthritis (SA); these tests are indicated in every suspected case. However,…
Abstract Number: 2259 • 2015 ACR/ARHP Annual Meeting
Incidence of Obesity, Diabetes and High Blood Pressure Associated with Arthritis: Analysis of the Canadian Longitudinal National Population Health Survey
Orit Schieir¹, Sheilah. Hogg-Johnson^1,2, Richard H Glazier^3,4,5,6 and Elizabeth M. Badley^1,7, ¹Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ²Institute for Work and Health, Toronto, ON, Canada, ³Family and Community Medicine, St. Michael's Hospital, Toronto, ON, Canada, ⁴Centre for Research on Inner City Health, St. Michael's Hospital, Toronto, ON, Canada, ⁵Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁶Family and Community Medicine, University of Toronto, Toronto, ON, Canada, ⁷Health Care & Outcomes Research, Toronto Western Res. Institute, Toronto, ON, Canada
Background/Purpose: While cross-sectional evidence points to a higher prevalence of cardiovascular (CVD) risk factors in persons with arthritis, longitudinal population based studies are lacking. The…
Abstract Number: 1346 • 2015 ACR/ARHP Annual Meeting
The Presentation and Outcomes of Surgically Treated Septic Arthritis: the Impact of Culture Results
Ziv Paz¹, Mary Louise Fowler², Clara Zhu³, Sarah B. Lieber¹, Andrew Moore⁴ and Robert H. Shmerling⁵, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²School of Medicine, Boston University School of Medicine, Boston, MA, ³Medical School, Boston University School of Medicine, Boston, MA, ⁴Medicine, Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, ⁵Medicine, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Clinically-suspected septic arthritis is culture-negative in 18-43% of cases. These patients are often treated surgically with associated morbidity, prolonged hospital stays and high medical…
Abstract Number: 2283 • 2015 ACR/ARHP Annual Meeting
Current and Lifetime Smoking Among US Adults with Arthritis: A Serious Clinical and Public Health Issue
Louise Murphy¹, Miriam G. Cisternas² and Teresa J. Brady¹, ¹Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ²MGC Data Services, Carlsbad, CA
Background/Purpose: Smoking's adverse effects include increased risk of joint replacement failure and decreased medication effectiveness (e.g., methotrexate, TNF blockers). Because little is known about the…
Abstract Number: 1347 • 2015 ACR/ARHP Annual Meeting
The Presentations and Outcomes of Prosthetic Joint Septic Arthritis: a Comparison of Culture-Positive and Culture-Negative Disease
Ziv Paz¹, Sarah B. Lieber¹, Andrew Moore², Clara Zhu³, Robert H. Shmerling⁴ and Mary Louise Fowler⁵, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Medicine, Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, ³Medical School, Boston University School of Medicine, Boston, MA, ⁴Medicine, Beth Israel Deaconess Medical Center, Boston, MA, ⁵School of Medicine, Boston University School of Medicine, Boston, MA
Background/Purpose: Prosthetic joint septic arthritis (PJSA) may complicate joint replacement in approximately 1-2% of cases. Synovial fluid cultures are negative in up to 25% of…
Abstract Number: 2372 • 2015 ACR/ARHP Annual Meeting
Timing of Onset and Cluster with Other Manifestations Influence the Spectrum of Arthritis in Anti Jo-1 Positive Antisynthetase Syndrome: Results from a Multicenter, International, Retrospective Study
Alberto Sifuentes Giraldo¹, Carlo Alberto Scirè², Santos Castañeda³, Laura Nuño⁴, Francisco Javier Lopez Longo⁵, Julia Martínez-Barrio⁵, Franco Franceschini⁶, Ilaria Cavazzana⁶, Paolo Airò⁷, Elena Bartoloni Bocci⁸, Javier Bachiller Corral⁹, Rossella Neri¹⁰, Simone Barsotti¹¹, Roberto Caporali¹², Carlomaurizio Montecucco¹³, Marcello Govoni¹⁴, Renato La Corte¹⁴, Federica Furini¹⁴, Florenzo Iannone¹⁵, Margherita Giannini¹⁶, Enrico Fusaro¹⁷, Simone Parisi¹⁸, Giuseppe Paolazzi¹⁹, Giovanni Barausse¹⁹, Raffaele Pellerito²⁰, Alessandra Russo²⁰, Lesley Ann Saketkoo²¹, Norberto Ortego-Centeno²², Luca Quartuccio²³, Christof Specker²⁴, Andreas Schwarting²⁵, Kostantinos Triantafyllias²⁶, Carlo Selmi²⁷, Fausto Salaffi²⁸, Marco Amedeo Cimmino²⁹, Annamaria Iuliano³⁰, Fabrizio Conti³¹, Gianluigi Baiocchi³², Elena Bravi³³, Veronica Codullo¹², Anna Ghirardello³⁴, Trinitario Pina³⁵, Miguel Angel Gonzalez-Gay³⁵, Lorenzo Cavagna¹³ and AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group, ¹Department of Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain, ²Epidemiology Unit – Italian Society for Rheumatology (SIR), Milano, Italy, ³Rheumatology, H.U. La Princesa, Madrid, Spain, ⁴Servicio de Reumatologia, Hospital Universitario La Paz, Madrid, Spain, ⁵Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁷Rheumatology Unit, Spedali Civili of Brescia, Brescia, Italy, ⁸Rheumatology Unit, Department of Clinical & Experimental Medicine, University of Perugia, Perugia, Italy, ⁹Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain, ¹⁰Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹¹Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹²Division of Rheumatology, University of Pavia, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, ¹³Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ¹⁴UOC Reumatologia, Azienda Ospedaliera Universitaria S. Anna, Ferrara, Italy, ¹⁵Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ¹⁶DIM, Rheumatology Unit, Bari, Italy, ¹⁷Department of Rheumatology, Città della Salute e della Scienza, Torino, Italy, ¹⁸Department of Rheumatology, Città Della Salute e della Scienza, Torino, Italy, ¹⁹Rheumatology Unit, Santa Chiara Hospital, Trento, Italy, ²⁰Division of Rheumatology, Mauriziano Hospital, Turin, Italy, ²¹Tulane University Lung Center, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²²Systemic Autoimmune Diseases Unit, Hospital Universitario San Cecilio, Granada, Spain, ²³Clinic of Rheumatology, Department of Medical and Biological Sciences (DSMB), Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy, ²⁴Department for Rheumatology and Clinical Immunology, St. Josef Krankenhaus, University Clinic, Essen, Germany, ²⁵Department of Internal Medicine, Rheumatology and Clinical Immunology, University Hospital Johannes-Gutenberg, Mainz, Germany, ²⁶ACURA Rheumatology Center, Bad Kreuznach, Germany, ²⁷Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano, Italy, ²⁸Rheumatology Department, Polytechnic University of Marche, C. Urbani Hospital, Jesi,, Ancona, Italy, ²⁹Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy, ³⁰Osp. San Camillo, Roma, Italy, ³¹Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ³²Rheumatology Unit, Department of Internal Medicine, S.Maria Hospital –IRCCS, Reggio Emilia, Italy, ³³Internal Medicine, Rheumatology Unit, Ospedale Guglielmo da Saliceto, Piacenza, Italy, ³⁴Department of Medicine-DIMED, University of Padova, Padova, Italy, ³⁵Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: arthritis, myositis and interstitial lung disease (ILD) are reported in up to 90% of patients affected by antisynthetase syndrome (ASSD) and thus represent the…
Abstract Number: 1355 • 2015 ACR/ARHP Annual Meeting
Ankle Periarthritis, a New Sign for Chikungunya : Ultrasound Study of Joint Lesions at the Acute Phase of Chikungunya
Lauren Brunier-Agot¹, Michel DeBandt², George Jean-Baptiste³, Regis Duvauferrier³, Catherine Lebris³ and Andre Cabié⁴, ¹Internal medicine and rheumatology, Zobda Quitman Hospital, Fort de France, Martinique, ²Medicine, Abstract Medical Int'l, Boulogne, France, ³Chu de Martinique, Fort de France, France, ⁴infectious disease, Zobda Quitman Hospital, Fort de France, Martinique
Background/Purpose: Chikungunya (CHIK) is a viral disease transmitted by the Aedes mosquito. The acute phase of the disease combines: fever, fatigue, arthralgia, arthritis, rash .…
Abstract Number: 2382 • 2015 ACR/ARHP Annual Meeting
An Outsourced Health-Enhancing Physical Activity Program for People with Rheumatoid Arthritis. Exploration of the Maintenance Phase
Christina H. Opava¹, Birgitta Nordgren¹, Cecilia Fridén¹, Ingrid Demmelmaier¹, Gunnar Bergström², Ingrid E. Lundberg³, Alyssa B. Dufour^1,4, Thomas Nessen¹ and PARA Study Group, ¹Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet, Huddinge, Sweden, ²Institute of Environmental Medicine, Unit of Intervention and Implementation Research, Karolinska Institutet, Stockholm, Sweden, ³Karolinska University Hospital, Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School & Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Health-enhancing physical activity (HEPA), i.e. at least 150 weekly minutes of moderate-intensity and at least twice-weekly muscle-strengthening activities, is recommended for every adult. Long-term studies on HEPA…

« Previous Page
1
…
8
9
10
11
12
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.